iBio Announces Positive Phase 1 Progress for IBIO-600, a Long-Acting Myostatin Antibody
The company dosed participants in the Phase 1 trial for IBIO-600, reporting no safety findings, and provided corporate updates on additional pipeline candidates. This positive clinical data signals progress for the biotech's obesity and cardiometabolic therapeutics.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day